Postoperative treatment of carvedilol following low dose landiolol has preventive effect for atrial fibrillation after coronary artery bypass grafting.
BACKGROUND
Postoperative atrial fibrillation (AF) is the most common complication after coronary artery bypass grafting (CABG). We have reported that the intra- and perioperative administration of landiolol has a preventive effect on postoperative AF in the early postoperative period after CABG surgery. The purpose of this study was to investigate the prophylactic effect of postoperative treatment with carvedilol following landiolol against postoperative AF.


METHODS
We reviewed all patients who underwent CABG from December 2005 and February 2009. Fifty-three patients underwent scheduled isolated CABG and were divided two groups; carvedilol group (n = 31), and control group (n = 22). Incidences of postoperative AF were noted.


RESULTS
There was no statistical difference between the two groups with regard to the occurrence of AF after CABG. The maximum ventricular rate of AF was significantly lower in the carvedilol group than in the control group. All patients with AF in the control group needed treatment for tachycardia, but this was not necessary in the carvedilol group.


CONCLUSIONS
Postoperative treatment with carvedilol following landiolol has the effect of preventing tachycardia during AF after coronary artery bypass grafting.
Yoshioka
I
I
Department of Cardiovascular Surgery, National Hospital Organization Sendai Medical Center, Sendai, Japan.
Sakurai
M
M
Namai
A
A
Kawamura
T
T
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000209:etiology / Q000517:prevention & control*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use*; D012189:Retrospective Studies; D013610:Tachycardia / Q000517:prevention & control; D016896:Treatment Outcome; D014508:Urea / Q000031:analogs & derivatives / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D009025:Morpholines; D011412:Propanolamines; D000077261:Carvedilol; C077049:landiolol; D014508:Urea